Literature DB >> 27679957

Transcriptional Analysis Reveals Evidence of Chronically Impeded ECM Turnover and Epithelium-to-Mesenchyme Transition in Scar Tissue Giving Rise to Marjolin's Ulcer.

Sarthak Sinha1, Samuel Su, Matthew Workentine, Natacha Agabalyan, Min Cheng, Vincent Gabriel, Jeff Biernaskie.   

Abstract

Marjolin's ulcer (MU) is an aggressive malignancy arising within chronic wounds. A major cause is unhealed burn injuries. This results in well-differentiated squamous cell carcinoma (SCC). This study aimed to elucidate transcriptional changes leading to malignancy by investigating differentially expressed genes in squamous cells present in a SCC compared with MU. MU tumor cells were isolated from histologically confirmed biopsy of SCC within an unhealed burn scar. Epithelial cells (ECs) adjacent to the tumor were co-isolated and a SCC cell line was commercially purchased. mRNA from all three samples was isolated and its expression was quantified using RNASeq. A threshold of log2fold change >2-fold in either direction was considered "differentially expressed." Gene expression analysis revealed distinct differences in gene expression in MU cells compared with EC (665 genes), EC and SCC (1673 genes). Enrichment analysis confirmed that pathways most affected included 1) elevation of genes associated with extracellular matrix organization/degradation, 2) activation of DNA damage, and 3) activation of cytokine signaling. Our analysis revealed two key insights about chronic wound microenvironment conducive to ulceration. First, in EC vs. MU comparison, downregulation of Collagen and Matrix metalloproteinase families suggests chronically impaired extracellular matrix turnover giving rise to a fibrotic microenvironment. Second, in SCC vs. MU comparison, dysregulation of cadherin-mediated cell-cell adhesions is suggestive of epithelial-to-mesenchymal transitions, similar to those during development. Acquisition of epithelial-to-mesenchymal transition may underlie the high metastatic rate in MU tumors. Taken together, this sheds light on mechanisms that underlie the divergent clinical features of these cutaneous cancers.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27679957     DOI: 10.1097/BCR.0000000000000432

Source DB:  PubMed          Journal:  J Burn Care Res        ISSN: 1559-047X            Impact factor:   1.845


  7 in total

Review 1.  The evolving relationship of wound healing and tumor stroma.

Authors:  Deshka S Foster; R Ellen Jones; Ryan C Ransom; Michael T Longaker; Jeffrey A Norton
Journal:  JCI Insight       Date:  2018-09-20

2.  Exploring the key genes and pathways in enchondromas using a gene expression microarray.

Authors:  Zhongju Shi; Hengxing Zhou; Bin Pan; Lu Lu; Yi Kang; Lu Liu; Zhijian Wei; Shiqing Feng
Journal:  Oncotarget       Date:  2017-07-04

Review 3.  Marjolin's ulcer in chronic wounds - review of available literature.

Authors:  Dariusz Bazaliński; Joanna Przybek-Mita; Beata Barańska; Paweł Więch
Journal:  Contemp Oncol (Pozn)       Date:  2017-09-29

4.  Nonmelanoma Skin Cancers: Embryologically Relevant Sites and UV Exposure.

Authors:  Giovanni Nicoletti; Marco Mario Tresoldi; Alberto Malovini; Borelli Francesco; Angela Faga
Journal:  Plast Reconstr Surg Glob Open       Date:  2020-04-07

5.  Marjolin's Tumor Complicating Chronic Periprosthetic Infection of a Total Knee Arthroplasty.

Authors:  Timothy Horan; Matthew T Wallace; Albert J Aboulafia; Janet D Conway
Journal:  J Bone Jt Infect       Date:  2019-04-20

Review 6.  Epidermolysis Bullosa-Associated Squamous Cell Carcinoma: From Pathogenesis to Therapeutic Perspectives.

Authors:  Angelo Giuseppe Condorelli; Elena Dellambra; Elena Logli; Giovanna Zambruno; Daniele Castiglia
Journal:  Int J Mol Sci       Date:  2019-11-14       Impact factor: 5.923

7.  Epidermolysis Bullosa in children: the central role of the pediatrician.

Authors:  Maria Rosaria Marchili; Giulia Spina; Marco Roversi; Cristina Mascolo; Elisabetta Pentimalli; Marialuisa Corbeddu; Andrea Diociaiuti; Maya El Hachem; Alberto Villani
Journal:  Orphanet J Rare Dis       Date:  2022-04-04       Impact factor: 4.123

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.